3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
25
Neoplasm Metastasis
2
Urogenital Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Oligometastatic Prostate Carcinoma
1
Neoplasms by Site
1
Neoplasms
1
Neoadjuvant Therapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Fatigue
1
Depression
1
Cancer Pain
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Radiosurgery
3
Androgen Antagonists
3
pembrolizumab
1
fludrocortisone acetate
1
enzalutamide
1
darolutamide
1
cabazitaxel
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Prednisone
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Hydrocortisone
1
Gonadotropin-Releasing Hormone
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostate Cancer Metastatic
×
Abiraterone Acetate
×
Clear all
NCT06136624
2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,310 enrolled